Novo Nordisk Canada launches a new Ozempic® savings program on May 29, 2026.
The initiative targets patients lacking public or private drug coverage.
The program aligns the brand-name drug's cost with generic alternatives.
This follows the recent approval and rollout of generic semaglutide in Canadian pharmacies.
Eligible Canadians will receive savings cards accepted nationwide, excluding Quebec.
Specific partners, including Rexall-operated Novo Nordisk Care® Rx, will apply the discount automatically.
The strategy helps patients maintain access to the brand-name medication.
Over one million Canadians currently use semaglutide.